Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
3/19/26 Rhythm (RYTM) Imcivree for Obesity Subscribers Only Subscribers Only Subscribers Only
3/19/26 Pfizer (PFE) Talzenna for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
3/17/26 Ascendis Pharma (ASND) Skytrofa for Turner Syndrome Subscribers Only Subscribers Only Subscribers Only
3/17/26 Greenwich LifeSciences (GLSI) GLSI-100 for HER2+ Breast Cancer Subscribers Only Subscribers Only Subscribers Only
3/16/26 Structure (GPCR) GSBR-1290 for Obesity Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results